

Targeting rare mutations in NSCLC: a focus on HER2m



Friday 22 March 2024 | 12:45–14:15 CET

South Hall 2, Prague Congress Centre, Prague, Czech Republic

12:45–12:55



Welcome and introduction

Prof. Egbert Smit (Chair)

Leiden University Medical Centre, Leiden, The Netherlands

12:55–13:15



Small numbers, big impact: the importance of testing for rare mutations in mNSCLC

Prof. Luka Brcic

Medical University of Graz, Graz, Austria

13:15–13:35



The evolving treatment landscape for rare mutations: focus on HER2m

Prof. Sonja Loges

University Medical Centre Mannheim, DKFZ, Heidelberg, Germany

13:35–13:55



Safety considerations for ADCs

Prof. Egbert Smit

Leiden University Medical Centre, Leiden, The Netherlands

13:55–14:15

Audience Q&A and closing remarks

Audience and Faculty



A promotional satellite symposium organised and funded by Daiichi Sankyo Europe GmbH and AstraZeneca PLC.

This meeting is for healthcare professionals only.

Daiichi Sankyo / AstraZeneca molecules may be discussed at this meeting.

AstraZeneca AB, SE 151 85 Södertälje, Sweden